Related Companies
|
[]
|
||||||||
Related Funds
|
[]
|
||||||||
English
|
|||||||||
oda_MaterialEventDisclosureGeneralAbstract|
|
|
||||||||
oda_UpdateAnnouncementFlag|
|
|
Hayır (No)
|
|||||||
oda_CorrectionAnnouncementFlag|
|
|
Hayır (No)
|
|||||||
oda_DateOfThePreviousNotificationAboutTheSameSubject|
|
|
-
|
|||||||
oda_DelayedAnnouncementFlag|
|
|
Hayır (No)
|
|||||||
oda_AnnouncementContentSection|
|
|
||||||||
oda_ExplanationSection|
|
|
||||||||
oda_ExplanationTextBlock|
|
Acting with the aim of becoming an important global actor in the pharmaceutical industry, Gen İlaç ve Sağlık Ürünleri Sanayi ve Ticaret A.Ş. ("GEN") follows the strategy of expanding its activities abroad in line with this aim. In line with this strategy, the Board of Directors of GEN has decided to open a Representative Office in Tbilisi, the capital of Georgia, in order to carry out marketing activities of products which are manufactured or registered by GEN or products which will be manufactured or registered by GEN and to carry out market research. With Georgia Representative Office , GEN will begin to operate in a new market, and it is considered that the Representative Office will expand the global activities of GEN and positively affect its sales. In addition to the Azerbaijan, Russia, Kazakhstan, Uzbekistan and Germany offices, Georgia Representative Office will operate as GEN's sixth office abroad. |
We proclaim that our above disclosure is in conformity with the principles set down in “Material Events Communiqué” of Capital Markets Board, and it fully reflects all information coming to our knowledge on the subject matter thereof, and it is in conformity with our books, records and documents, and all reasonable efforts have been shown by our Company in order to obtain all information fully and accurately about the subject matter thereof, and we’re personally liable for the disclosures.